Citigroup’s Envoy Medical COCH Stock Holding History

Citigroup’s Portfolio COCH Stock Details COCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-215	Closed	-$143	–	5800
2026 Q1	$143	Buy	215 +214	+21,400%	+$146	﹤0.01%	5595
2025 Q4	$1	Sell	1 -70	-99%	-$55	﹤0.01%	5963
2025 Q3	$55	Buy	+71	New	+$96	﹤0.01%	5846

Other funds holding COCH

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCA

DSG Capital Advisors Edina, Minnesota $704M AUM 34.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACP

Arcus Capital Partners Atlanta, Georgia $242M AUM 20.33% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Citigroup's COCH Position: Q2 2026 in Review

Citigroup sold out of Envoy Medical (COCH) in Q2 2026, closing a stake of 215 shares — an estimated $143 sold.

Citigroup first reported a position in COCH in Q3 2025 and held it in 3 quarters. The position peaked at $143 in Q1 2026. 32 funds tracked by Wall St. Rank hold COCH as of Q2 2026.

Citigroup reported no remaining Envoy Medical position as of Q2 2026 after selling out during the quarter.
Citigroup sold 215 Envoy Medical shares in Q2 2026, an estimated $143.
Citigroup first reported a position in Envoy Medical in Q3 2025 and held it in 3 quarters.
Citigroup's Envoy Medical position peaked at $143 in Q1 2026.
32 funds tracked by Wall St. Rank held Envoy Medical as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.